Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies
暂无分享,去创建一个
I. Dotan | S. Fishman | T. Ziv-Baran | H. Yanai | Y. Ron | G. Rosner | O. Icht | A. Yaron | A. Waizbard
[1] T. Kim,et al. Efficacy of Adalimumab in Korean Patients with Crohn’s Disease , 2015, Gut and liver.
[2] A. Bitton,et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial , 2015, The Lancet.
[3] M. Kamm,et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis , 2015, Alimentary pharmacology & therapeutics.
[4] M. Barreiro-de Acosta,et al. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice , 2015, European journal of gastroenterology & hepatology.
[5] J. Gisbert,et al. Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naive to Anti-TNF Therapy , 2015, Journal of clinical gastroenterology.
[6] E. Louis,et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. , 2015, Gastroenterology.
[7] A. Amiot,et al. Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID , 2014, The American Journal of Gastroenterology.
[8] Leyla J. Ghazi,et al. Step Up Versus Early Biologic Therapy for Crohn's Disease in Clinical Practice , 2013, Inflammatory bowel diseases.
[9] D. Rubin,et al. Response to biologic therapy in Crohn's disease is improved with early treatment: An analysis of health claims data , 2012, Inflammatory bowel diseases.
[10] P. Rutgeerts,et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.
[11] P. Moayyedi,et al. Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.
[12] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[13] C. O'Morain,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.
[14] M. Vos,et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.
[15] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[16] W. Sandborn,et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] W. Tremaine,et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.
[18] A. Forbes,et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.
[19] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[20] M. Bala,et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.
[21] B. Feagan. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[23] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[24] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[25] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[26] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[27] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[28] P. Munkholm,et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.
[29] S. Hanauer,et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.